Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.
Kwak Y et al. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells. Mol Cancer Ther14:2292-302 (2015).
Read more (PubMed: 26294741) »
Doughton G et al. Formation of a polarised primitive endoderm layer in embryoid bodies requires fgfr/erk signalling. PLoS One9:e95434 (2014).
Read more (PubMed: 24752320) »
Gavine PR et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res72:2045-56 (2012).
Read more (PubMed: 22369928) »